Anika Therapeutics (ANIK) Long-Term Deferred Tax (2010 - 2026)

Anika Therapeutics (ANIK) has 10 years of Long-Term Deferred Tax data on file, last reported at $1.2 million in Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 3.2% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 3.2% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, up 8.33% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $1.2 million, down from $1.3 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for ANIK reached as high as $1.5 million in Q1 2023 and fell as low as $1.2 million in Q1 2026.
• Historically, Long-Term Deferred Tax has averaged $1.3 million across 5 years, with a median of $1.3 million in 2024.
• Across the five-year window, Long-Term Deferred Tax retreated 20.95% in 2024 and gained 8.33% in 2025, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $1.4 million in 2022, then increased by 2.76% to $1.5 million in 2023, then fell by 20.95% to $1.2 million in 2024, then increased by 8.33% to $1.3 million in 2025, then declined by 9.8% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $1.2 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.